Catalent investing $5m to bolster early development offering

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/lovelyday12)
(Image: Getty/lovelyday12)
Catalent plans to invest $5m to create a new drug development center of excellence focusing on preclinical to clinical phase IIb formulation, analytical, and manufacturing solutions.

The delivery technologies and development solutions provider this week announced the investment, which will establish its Somerset, NJ facility and headquarters as a center of excellence (CoE) focused on early phase formulation, analytical, and manufacturing solutions for orally delivered small molecules.

“There is a big trend in the industry where the molecules are getting more and more complex, both on the development side and the manufacturing side,” ​said Elliott Berger, VP of global marketing and strategy at Catalent.

“They need more expertise, they need more technology, they need more focus to get them through the system so they don’t fail for formulation purposes,” ​he explained. “There are plenty of other problems to overcome in this industry; you don’t need to fail for formulation purposes​.”

Catalent is currently working on the expansion plans, Berger told us at CPhI North America, explaining that the company needs “some additional pilot-scale equipment [and] some additional lab equipment.”

“We also need some additional expertise to move these molecules around faster through the process,”​ he added.

However, the company is going to start talking to customers before any plans are solidified. Berger said: “We didn’t want to do a lot of planning until we talked to all the customers. Some of the stuff needs to be done in conjunction with the customer and we want to make sure we do it in a way that they would like it done.”

According to the company, the investment also will build on the site’s modified release formulation development capabilities, bioavailability solutions, and its application of OptiMelt hot melt extrusion (HME) technology.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us


View more